Device Trial Radar · NCT02270931
A Prospective Longitudinal Breast Cancer Study
Last checked: Nov 20, 2026Latest source record: Aug 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Planned (sponsor's estimate)
Start
May 2014
Primary completion
Jun 30, 2021
Study completion Jun 30, 2021
Sponsor
- Lead sponsor
- Fujirebio Diagnostics, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 22, 2014
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of breast cancer.
Conditions
- Breast Cancer
Interventions
CA 15-3 AssayDevice
Physicians use the CA 15-3 test result to manage their patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Measure CA 15-3 in Breast Cancer PatientsTime frame: 3 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Jane Skelton, MD
Boca Raton, Florida
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.